Beyond creams.
Without an injection step.
ExoGenis is building a clinic-led biologic delivery platform based on controlled microtip technology.
Our first commercial format uses partner-manufactured microtips within professional skin protocols.
We are starting with a focused clinic use case while continuing to develop our proprietary platform for broader biologic delivery and selected future dermatology applications.
Initial clinic focus: post-procedure care and between-treatment maintenance.
- Skin delivery infrastructure
A new category of controlled skin delivery
ExoGenis is developing a new category of controlled regenerative skin delivery positioned between passive topical skincare and injectable procedures. The platform is designed to support standardized, clinic-guided delivery pathways that fit naturally into professional dermatology and aesthetic practice.
.svg)
Professional
Delivery Format
Controlled
Delivery
.svg)
Clinic-Guided
Protocols
- DELIVERY SYSTEM ARCHITECTURE
Controlled upper skin delivery
ExoGenis combines a removable delivery layer with dissolvable microtips to support localized delivery of regenerative skin actives into the upper skin. Designed for controlled application within professional clinic workflows.
- Clinic Workflow
Designed to fit professional skin
workflows
ExoGenis complements selected dermatology and aesthetic procedures, supporting structured post-procedure care without requiring additional capital equipment.
This architecture is being developed to support defined dosing, clean application and repeatable use across clinical protocols.
After Selected Procedures
Designed to complement selected dermatology and aesthetic treatments.
Controlled Delivery
Localized upper-skin delivery
using dissolvable microtips.
Clinic-GUIDED continuation
Supports structured care between clinic
visits according to professional guidance.
Follow-up
Supports structured follow-up, adherence tracking,
and future treatment planning.
The missing layer between treatments
Bridging the gap between surface-level topicals and invasive injectables.
TOPICALS
Penetration-limited
Conventional topicals largely remain near the surface and can show variable absorption.
MICROINFUSION
Variable / manual
Manual or device-assisted delivery can vary by technique, depth, pressure, and distribution.
EXOGENIS Delivery system
Controlled / repeatable
Designed to deliver defined formulation amounts through a controlled dissolvable microtip array
INJECTIONS
Invasive / deeper
Can bypass the skin barrier, but adds invasiveness, complexity, and injector dependency.
- Why Clinics May Add ExoGenis
Adding controlled delivery without new equipment.
.svg)
Structured protocol feedback
Capture clinic and patient feedback during pilot use to support protocol refinement and future validation.
Clinic-guided continuity
Supports structured between-treatment care, repeat protocols, and stronger patient connection to the clinic.
Partner-led validation
Built for selected clinic and industry partners who want to participate in early workflow, usability, and protocol validation.
Apply for Pilot Access
We are currently collaborating with professional and validation partners to evaluate the ExoGenis biologic delivery system during its technical validation phase. Register your interest to learn more about pilot participation.
A clinic-controlled delivery layer between procedures.
Designed for controlled use
.svg)
Payload Compatibility
- Designed for fragile active formulations.
- Microtip/coating architecture under development.
- MVP: exosome-associated formulation first.
.svg)
Safety-Oriented Design
- Single-use format.
- No retained solid needles.
- Designed for controlled upper-skin interaction.
.svg)
Validation Pathway
- Ex vivo skin interaction studies completed.
- Ex vivo skin interaction studies completed.
- Human tolerability and workflow validation planned.
Built with technical
and clinical validation partners
ExoGenis is being developed with scientific, technical, and commercialization partners across biologic delivery, platform validation, skin model testing, and early market validation.
Innovationsfonden — non-dilutive funding for technology development
Sono-Tek — coating technology validation for biologic deposition
BioIVT — ex-vivo skin model testing for delivery performance
MedTech Growth — DTU Science Park accelerator program for medical technology companies
Beyond Beta — accelerator support and early-stage validation
Innovationsfonden — non-dilutive funding for technology development
Sono-Tek — coating technology validation for biologic deposition
BioIVT — ex-vivo skin model testing for delivery performance
MedTech Growth — DTU Science Park accelerator program for medical technology companies
Beyond Beta — accelerator support and early-stage validation
- Ambition
Building the missing delivery layer between topicals and injections
Our ambition is to build Denmark's first dermatology-focused biologic delivery platform: A controlled delivery layer between topical skincare and injectable procedures.
ExoGenis starts with regenerative dermatology and clinic-integrated skin protocols, with longer-term potential across broader biologic delivery applications in skin.
Interested in piloting ExoGenis?
We are looking for strategic partners in the professional skin care and dermatology space to join our exclusive pilot program.
Professional and partner access only during validation phase.
Stay informed about our technology and future availability. Talk to us